Medicare opens a highway for AI agents in healthcare

Reimbursement, the lifeblood of AI in healthcare

The debate around medical artificial intelligence often focuses on model performance, diagnostic quality, or data security. But in practice, large-scale adoption depends on a far more prosaic factor: who pays, and for what. It is precisely on this front that Medicare, the U.S. public health insurance program intended in particular for people aged over 65, is sending a major signal.

As TechCrunch noted in an article titled “Medicare’s new payment model is built for AI, and most of the tech world has no idea”, the new payment framework introduced in the United States could create unprecedented room for AI agents responsible for monitoring patients between appointments. In other words, the issue is not only about sophisticated chatbots or copilots for physicians, but about systems capable of handling coordination, follow-up reminders, therapeutic education, and remote monitoring tasks.

The issue is strategic, because the recent history of digital health shows one constant: even a high-performing tool struggles to gain traction as long as no clear reimbursement mechanism exists. Conversely, when a payer as influential as Medicare recognizes an activity and agrees to fund it, the entire ecosystem can reorganize around that new incentive.

What Medicare’s new payment model changes

The key point highlighted by TechCrunch is that Medicare does not pay only for a conventional face-to-face medical service. The mechanism paves the way for recognizing the value of work carried out between appointments, particularly for longitudinal patient monitoring. In this framework, software agents can become economically relevant if they make it possible to document, automate, or extend tasks currently handled by clinical or administrative staff.

In concrete terms, the intended uses concern functions already clearly identified in care pathways:

• follow-up reminders after hospitalization or an appointment;
• monitoring treatment adherence;
• collecting patient data at home;
• coordination between professionals;
• triaging weak signals that require human intervention;
• monitoring patients with chronic illnesses.

The change is less spectacular than a new large language model, but potentially more structural. Medicare covers more than 65 million Americans. When a payment framework is adjusted at that scale, it is not merely a regulatory test: it is a market signal. Software publishers, hospitals, supplemental insurers, remote monitoring providers, and investors can see in it the promise of a more readable business model.

The logic is simple: if an AI system enables a practice or facility to properly carry out, record, and bill for clinical follow-up between two visits, it stops being an experimental gadget and becomes a productivity and revenue tool. This is the shift that many technology players, according to TechCrunch, still underestimate.

Why AI agents are particularly well positioned

Over the past two years, the term “AI agent” has become established to describe software capable of chaining actions together, interacting with business systems, following up with a patient, summarizing responses, or alerting a professional according to given rules. In healthcare, this category of tools finds a particularly concrete field of application here.

Follow-up between appointments is indeed a gray area of the healthcare system. It requires a great deal of time, but remains difficult to organize. Patients forget instructions, respond late, fail to report certain side effects, or drop out of the care pathway. On the care provider side, teams lack the time to systematically call, check how symptoms are evolving, or document every interaction.

An AI agent can intervene at several levels:

• send personalized, multichannel messages;
• ask structured questions about symptoms or medication intake;
• detect abnormal responses and escalate to a nurse or physician;
• pre-fill reports in the patient record;
• ensure continuity of contact at low marginal cost.

The value of these tools therefore does not rest solely on their “intelligence,” but on their ability to fit into a billing and compliance chain. This is where the Medicare model becomes decisive. If reimbursement covers the service provided over time, rather than only the one-off service, then automating follow-up becomes a direct lever for transformation.

This development could favor a new generation of startups, less focused on pure diagnosis than on clinical orchestration. Players specializing in chronic disease management, post-operative care, outpatient oncology, or mental health could benefit quickly. The market could also attract major electronic medical record publishers, already well positioned to integrate these functions at the heart of workflows.

A lesson for Europe and France

From a French perspective, the issue deserves particular attention. The European debate on AI in healthcare often focuses on regulation, certification, and data protection, rightly so. But funding remains the main barrier. Without a coverage model, facilities test, physicians experiment, but deployments remain limited.

France already has useful building blocks, such as reimbursement for medical remote monitoring for certain conditions, or experiments carried out as part of organizational innovation. Health Insurance and the High Authority for Health have begun to structure the evaluation of certain digital tools. Yet industrial-scale rollout remains slow, particularly for solutions that fall under neither a simple medical device nor a traditional medical service.

The U.S. signal is a reminder of one reality: the most profitable medical AI in the short term will not necessarily be the kind that replaces physicians in an expert task, but the kind that fills the blind spots in care. In France as elsewhere in Europe, needs are massive: an aging population, pressure on the medical workforce, an explosion in chronic illnesses, hospital overcrowding, and the need to better coordinate community-based care and facilities.

In this context, agents capable of providing semi-automated follow-up could address very concrete needs. But a framework must make it possible to pay for this work. Failing that, AI will remain confined to pilots funded through innovation budgets, without any real diffusion into routine clinical practice.

The limitations: security, liability, and the risk of windfall effects

Opening up a favorable reimbursement model does not mean that all obstacles disappear. In healthcare, automating patient interaction raises sensitive questions. An AI agent monitoring a patient remotely may miss a weak signal, misinterpret a response, or create a false impression of continuous monitoring. Medical-legal liability remains central: who is responsible in the event of a detection failure or delayed escalation?

The clinical quality of the tools will also have to be demonstrated. A system that automatically sends reminders does not have the same scope as an agent that assesses symptoms or prioritizes alerts. The greater the software’s autonomy, the stronger the requirements for validation, traceability, and auditability.

There is also a risk of a windfall effect. As soon as a reimbursement code appears, some players seek to optimize billing even before proving clinical usefulness. U.S. authorities have already experienced this type of drift in other segments of digital health. The success of the new framework will therefore depend on the ability to distinguish tools that genuinely improve care pathways from those that merely dress up administrative workflows with a layer of generative AI.

Another point requiring vigilance is patient acceptability. Some will appreciate more frequent and simpler interactions. Others will refuse to entrust sensitive information to a conversational agent, especially if the boundary between human and machine is not clearly explained. Transparency about the role of AI, the terms of human oversight, and the use of data will be decisive.

The next competitive front for medical AI

What the Medicare move reveals is that the next battle in healthcare AI will be fought as much in fee schedules and payment channels as in model laboratories. The biggest winners will not necessarily be those with the best technical demonstrations, but those able to turn automation capabilities into reimbursable, measurable services that can be integrated into practices.

For investors, this changes the analytical framework. An AI healthcare startup is no longer valued solely for its technology engine, but for its alignment with the incentives of the healthcare system. For hospitals and practices, the question is no longer only “does the tool work?”, but “can it fit into a sustainable model?”. And for European regulators, the issue is becoming more urgent: let other markets alone define the economic standards of clinical AI, or build funding mechanisms suited to local realities.

If the U.S. precedent is confirmed, it could accelerate the emergence of a less spectacular but far more pervasive medical AI: discreet agents connected to patient records, capable of maintaining contact, documenting follow-up, and streamlining care pathways. In a sector where attention has focused on the promises of large models, Medicare is bluntly reminding us of an old rule in healthcare: what truly transforms the market is not only what technology can do, but what the system finally agrees to pay for.